|
1.Elbaz, A., et al., Epidemiology of Parkinson's disease. Revue neurologique, 2016. 172(1): p. 14-26. 2.Liu, C.-C., et al., Variations in incidence and prevalence of Parkinson’s disease in Taiwan: a population-based nationwide study. Parkinson’s Disease, 2016. 2016. 3.Lotharius, J. and P. Brundin, Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci, 2002. 3(12): p. 932-42. 4.Pakkenberg, B., et al., The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry, 1991. 54(1): p. 30-3. 5.Alexander, G.E., Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues in clinical neuroscience, 2022. 6.Jankovic, J. and E.K. Tan, Parkinson’s disease: Etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry, 2020. 91(8): p. 795-808. 7.Heinzel, S., et al., Update of the MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 2019. 34(10): p. 1464-1470. 8.Braak, H., et al., Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). Journal of neurology, 2002. 249: p. iii1-iii5. 9.Mahlknecht, P., K. Seppi, and W. Poewe, The concept of prodromal Parkinson’s disease. Journal of Parkinson's disease, 2015. 5(4): p. 681-697. 10.Srinivasan, E., et al., Alpha-synuclein aggregation in Parkinson's disease. Frontiers in medicine, 2021. 8: p. 736978. 11.Wakabayashi, K., et al., The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of α‐synuclein aggregates. Neuropathology, 2007. 27(5): p. 494-506. 12.Postuma, R.B., et al., MDS clinical diagnostic criteria for Parkinson's disease. Movement disorders, 2015. 30(12): p. 1591-1601. 13.Armstrong, M.J. and M.S. Okun, Diagnosis and treatment of Parkinson disease: a review. Jama, 2020. 323(6): p. 548-560. 14.Suwijn, S.R., et al., The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI research, 2015. 5(1): p. 1-8. 15.Tieu, K., A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harbor perspectives in medicine, 2011. 1(1): p. a009316. 16.Berger, K., S. Przedborski, and J.L. Cadet, Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res Bull, 1991. 26(2): p. 301-7. 17.Blandini, F., et al., Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur J Neurosci, 2007. 25(2): p. 397-405. 18.Przedborski, S., et al., Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience, 1995. 67(3): p. 631-47. 19.Sauer, H. and W. Oertel, Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience, 1994. 59(2): p. 401-415. 20.Eagle, A.L., O.O. Olumolade, and H. Otani, Partial dopaminergic denervation-induced impairment in stimulus discrimination acquisition in parkinsonian rats: a model for early Parkinson's disease. Neurosci Res, 2015. 92: p. 71-9. 21.Issy, A.C., et al., Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease. Life Sci, 2015. 125: p. 71-8. 22.Shin, E., et al., Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Exp Neurol, 2014. 257: p. 25-38. 23.Xue, Y.Q., et al., AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Gene Ther, 2010. 17(1): p. 83-94. 24.Branchi, I., et al., Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res, 2008. 86(9): p. 2050-61. 25.Tadaiesky, M.T., et al., Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience, 2008. 156(4): p. 830-40. 26.Deumens, R., A. Blokland, and J. Prickaerts, Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Experimental neurology, 2002. 175(2): p. 303-317. 27.Butt, M.F., et al., The anatomical basis for transcutaneous auricular vagus nerve stimulation. J Anat, 2020. 236(4): p. 588-611. 28.Zhao, Y.N., et al., Transcutaneous electrical cranial-auricular acupoints stimulation (TECAS) for treatment of the depressive disorder with insomnia as the complaint (DDI): A case series. Brain Stimul, 2022. 15(2): p. 485-487. 29.Morris, R., et al., Noninvasive vagus nerve stimulation to target gait impairment in Parkinson's disease. Movement Disorders, 2019. 34(6): p. 918-919. 30.Farrand, A.Q., et al., Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease. Brain stimulation, 2017. 10(6): p. 1045-1054. 31.Kaniusas, E., et al., Current directions in the auricular vagus nerve stimulation I–a physiological perspective. Frontiers in neuroscience, 2019: p. 854. 32.Boehmer, A.A., et al., Acupuncture at the auricular branch of the vagus nerve enhances heart rate variability in humans: An exploratory study. Heart Rhythm O2, 2020. 1(3): p. 215-221. 33.He, W., et al., Auricular acupuncture and vagal regulation. Evid Based Complement Alternat Med, 2012. 2012: p. 786839. 34.Kaniusas, E., et al., Current Directions in the Auricular Vagus Nerve Stimulation I - A Physiological Perspective. Front Neurosci, 2019. 13: p. 854. 35.Park, J., J.Y. Oh, and H.J. Park, Potential role of acupuncture in the treatment of Parkinson's disease: A narrative review. Integr Med Res, 2023. 12(2): p. 100954. 36.Liu, Y., et al., Efficacy and safety of electroacupuncture at auricular concha region in promoting of rehabilitation of ischemic stroke patients with upper limb motor dysfunction: A study protocol for a randomized pilot trial. Medicine (Baltimore), 2022. 101(15): p. e28047. 37.Wang, L., et al., The efficacy and safety of transcutaneous auricular vagus nerve stimulation in patients with mild cognitive impairment: A double blinded randomized clinical trial. Brain Stimul, 2022. 15(6): p. 1405-1414. 38.Peng, L., et al., Transauricular vagus nerve stimulation at auricular acupoints Kindey (CO10), Yidan (CO11), Liver (CO12) and Shenmen (TF4) can induce auditory and limbic cortices activation measured by fMRI. Hear Res, 2018. 359: p. 1-12. 39.Campos, F.L., et al., Rodent models of Parkinson's disease: beyond the motor symptomatology. Frontiers in behavioral neuroscience, 2013. 7: p. 175. 40.Paxinos, G. and C. Watson, The Rat Brain in Stereotaxic Coordinates . 2005: Elsevier Academic Press. San Diego, 2005. 41.Saghaei, M., Random allocation software for parallel group randomized trials. BMC Med Res Methodol, 2004. 4: p. 26. 42.Campos, F.L., et al., Rodent models of Parkinson's disease: beyond the motor symptomatology. Front Behav Neurosci, 2013. 7: p. 175. 43.Korol, D.L., et al., Involvement of lactate transport in two object recognition tasks that require either the hippocampus or striatum. Behav Neurosci, 2019. 133(2): p. 176-187. 44.Lee, D.Y., Y.R. Jiu, and C.L. Hsieh, Metabolism modulation in rat tissues in response to point specificity of electroacupuncture. Sci Rep, 2022. 12(1): p. 210. 45.Meade, R.M., D.P. Fairlie, and J.M. Mason, Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles. Mol Neurodegener, 2019. 14(1): p. 29. 46.Zeng, B.Y., et al., 6-Hydroxydopamine lesioning differentially affects alpha-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats. Neurosci Lett, 2002. 322(1): p. 33-6. 47.Mishra, A. and S. Krishnamurthy, Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with alpha-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson's Model in Rats. Neurotox Res, 2019. 35(3): p. 542-562. 48.Shan, S., L. Tian, and R. Fang, Chlorogenic Acid Exerts Beneficial Effects in 6-Hydroxydopamine-Induced Neurotoxicity by Inhibition of Endoplasmic Reticulum Stress. Med Sci Monit, 2019. 25: p. 453-459. 49.Li, X., et al., Neuroprotective effects of kukoamine A on 6-OHDA-induced Parkinson's model through apoptosis and iron accumulation inhibition. Chinese Herbal Medicines, 2021. 13(1): p. 105-115. 50.Zhang, Y., et al., Echinacoside's nigrostriatal dopaminergic protection against 6-OHDA-Induced endoplasmic reticulum stress through reducing the accumulation of Seipin. J Cell Mol Med, 2017. 21(12): p. 3761-3775. 51.Xu, Z., et al., Astragaloside IV Protects 6-Hydroxydopamine-Induced SH-SY5Y Cell Model of Parkinson’s Disease via Activating the JAK2/STAT3 Pathway. Frontiers in Neuroscience, 2021. 15. 52.Choi, D.-H., et al., The Role of NOX4 in Parkinson’s Disease with Dementia. International Journal of Molecular Sciences, 2019. 20(3): p. 696. 53.Stefanis, L., α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med., 2012. 2: p. a009399. 54.Vidović, M. and M.G. Rikalovic, Alpha-synuclein aggregation pathway in Parkinson’s disease: current status and novel therapeutic approaches. Cells, 2022. 11(11): p. 1732. 55.Lee, P., et al., The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. Journal of neural transmission, 2006. 113: p. 1435-1439. 56.Hansson, O., et al., Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimer's research & therapy, 2014. 6(3): p. 1-6. 57.Parnetti, L., et al., Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis. Biomarkers in medicine, 2016. 10(1): p. 35-49. 58.Ganguly, U., et al., Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough. Front Aging Neurosci, 2021. 13: p. 702639. 59.Hol, E.M. and M. Pekny, Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Current opinion in cell biology, 2015. 32: p. 121-130. 60.Miyazaki, I. and M. Asanuma, Neuron-Astrocyte Interactions in Parkinson's Disease. Cells, 2020. 9(12). 61.Singh, S., et al., Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease. Indian J Exp Biol, 2006. 44(9): p. 699-704. 62.Berghauzen-Maciejewska, K., et al., Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson's disease: an influence of chronic pramipexole in rats. PLoS One, 2015. 10(3): p. e0117698. 63.Hernandez-Chan, N.G., et al., Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease. J Biomed Sci, 2015. 22: p. 59. 64.Levivier, M., et al., Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci, 1995. 15(12): p. 7810-20. 65.Miyazaki, I. and M. Asanuma, Neuron-astrocyte interactions in Parkinson’s disease. Cells, 2020. 9(12): p. 2623. 66.Booth, H.D., W.D. Hirst, and R. Wade-Martins, The role of astrocyte dysfunction in Parkinson’s disease pathogenesis. Trends in neurosciences, 2017. 40(6): p. 358-370. 67.Porter, A.G. and R.U. Jänicke, Emerging roles of caspase-3 in apoptosis. Cell death & differentiation, 1999. 6(2): p. 99-104. 68.Hanrott, K., et al., 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cδ. Journal of biological chemistry, 2006. 281(9): p. 5373-5382. 69.Spina, M.B., et al., Brain‐derived neurotrophic factor protects dopamine neurons against 6‐hydroxydopamine and N‐methyl‐4‐phenylpyridinium ion toxicity: involvement of the glutathione system. Journal of neurochemistry, 1992. 59(1): p. 99-106. 70.Howells, D., et al., Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Experimental neurology, 2000. 166(1): p. 127-135. 71.Jin, W., Regulation of BDNF-TrkB signaling and potential therapeutic strategies for Parkinson’s disease. Journal of Clinical Medicine, 2020. 9(1): p. 257. 72.Blandini, F., R.H. Porter, and J.T. Greenamyre, Glutamate and Parkinson's disease. Mol Neurobiol, 1996. 12(1): p. 73-94. 73.Blandini, F., An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct Neurol, 2010. 25(2): p. 65-71. 74.Ambrosi, G., S. Cerri, and F. Blandini, A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease. J Neural Transm (Vienna), 2014. 121(8): p. 849-59. 75.Tobon-Velasco, J.C., et al., Early toxic effect of 6-hydroxydopamine on extracellular concentrations of neurotransmitters in the rat striatum: an in vivo microdialysis study. Neurotoxicology, 2010. 31(6): p. 715-23. 76.Li, X., et al., Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci, 2010. 30(5): p. 1788-97. 77.Sharma, N., S. Jamwal, and P. Kumar, Beneficial effect of antidepressants against rotenone induced Parkinsonism like symptoms in rats. Pathophysiology, 2016. 23(2): p. 123-34. 78.Singh, S., S. Jamwal, and P. Kumar, Neuroprotective potential of Quercetin in combination with piperine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Neural Regen Res, 2017. 12(7): p. 1137-1144. 79.Troshev, D., et al., Striatal Neurons Partially Expressing a Dopaminergic Phenotype: Functional Significance and Regulation. Int J Mol Sci, 2022. 23(19). 80.Daubner, S.C., T. Le, and S. Wang, Tyrosine hydroxylase and regulation of dopamine synthesis. Archives of biochemistry and biophysics, 2011. 508(1): p. 1-12. 81.Kim, S.-N., et al., Acupuncture enhances the synaptic dopamine availability to improve motor function in a mouse model of Parkinson's disease. PLoS One, 2011. 6(11): p. e27566. 82.Cano-Colino, M., R. Almeida, and A. Compte, Serotonergic modulation of spatial working memory: predictions from a computational network model. Front Integr Neurosci, 2013. 7: p. 71. 83.Cano-Colino, M., et al., Serotonin regulates performance nonmonotonically in a spatial working memory network. Cereb Cortex, 2014. 24(9): p. 2449-63. 84.Munoz, A., et al., Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson's Disease and Adverse Effects of L-DOPA. Front Neuroanat, 2020. 14: p. 26. 85.Caligiore, D., et al., Increasing Serotonin to Reduce Parkinsonian Tremor. Front Syst Neurosci, 2021. 15: p. 682990. 86.Reed, M.C., H.F. Nijhout, and J. Best, Computational studies of the role of serotonin in the basal ganglia. Front Integr Neurosci, 2013. 7: p. 41. 87.Chen, H.C., et al., TRPV1 is a Responding Channel for Acupuncture Manipulation in Mice Peripheral and Central Nerve System. Cell Physiol Biochem, 2018. 49(5): p. 1813-1824. 88.da Silva, J.R., M.L. da Silva, and W.A. Prado, Electroacupuncture at 2/100 hz activates antinociceptive spinal mechanisms different from those activated by electroacupuncture at 2 and 100 hz in responder rats. Evid Based Complement Alternat Med, 2013. 2013: p. 205316. 89.Liang, Y., et al., Influence of electroacupuncture at acupoints Zusanli(ST 36) and Taichong(LR 3) with different frequencies on rats swimming endurance. Journal of Acupuncture and Tuina Science, 2006. 4(5): p. 261-263. 90.Napadow, V., et al., Correlating acupuncture FMRI in the human brainstem with heart rate variability. Conf Proc IEEE Eng Med Biol Soc, 2005. 2005: p. 4496-9. 91.Wu, Y.Y., et al., Effects of Electroacupuncture with Dominant Frequency at SP 6 and ST 36 Based on Meridian Theory on Pain-Depression Dyad in Rats. Evid Based Complement Alternat Med, 2015. 2015: p. 732845.
|